Likewise, in combination with paclitaxel as first line treatment, lapatinib showed a better rate of overall survival compared with placebo plus paclitaxel in metastatic HER2 positive BC patients (20.5 vs. 27.8 months HR 0.74) [79]. The gene discussed is ERBB2; the disease is breast cancer.